دورية أكاديمية
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
| العنوان: | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. |
|---|---|
| المؤلفون: | Chan, John K, Deng, Wei, Higgins, Robert V, Tewari, Krishnansu S, Bonebrake, Albert J, Hicks, Michael, Gaillard, Stephanie, Ramirez, Pedro T, Chafe, Weldon, Monk, Bradley J, Aghajanian, Carol |
| المصدر: | Gynecologic oncology, vol 146, iss 3 |
| بيانات النشر: | eScholarship, University of California |
| سنة النشر: | 2017 |
| المجموعة: | University of California: eScholarship |
| مصطلحات موضوعية: | Humans, Carcinoma, Neoplasm Recurrence, Local, Disease Progression, Triazines, Alanine, Antineoplastic Agents, Disease-Free Survival, Retreatment, Survival Rate, Adult, Aged, 80 and over, Middle Aged, Uterine Cervical Neoplasms, Female, Early Termination of Clinical Trials, Response Evaluation Criteria in Solid Tumors, Brivanib, Recurrent cervical carcinoma, Clinical Trials and Supportive Activities, Prevention, Digestive Diseases, Hematology, Patient Safety, Cancer, Clinical Research, Rare Diseases, 6.1 Pharmaceuticals |
| جغرافية الموضوع: | 554 - 559 |
| الوصف: | BackgroundBrivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR). We studied its efficacy and tolerability in persistent or recurrent cervical cancer patients.MethodsEligible patients had at least one prior cytotoxic regimen for recurrence and with measurable disease. Brivanib 800mg was administered orally every day (1cycle=28days) until disease progression or prohibitive toxicity. Primary endpoints were progression-free survival (PFS) >6months and objective tumor response.ResultsOf 28 eligible and evaluable women enrolled, 11 (39%) had primary surgery and 25 (89%) had prior radiation. Eighteen (64%) received one prior cytotoxic treatment and 10 (36%) had 2 prior regimens. Twelve (43%) had >2cycles of brivanib with 4 (14%) receiving >10cycles (range: 1-20). Seven (25%) patients had PFS >6months (90% CI: 7.3%-33.9%). Two (7%) (90% CI: 1.3%-20.8%) patients had partial tumor response with duration of 8 and 22months and 12 (43%) had stable disease. The median PFS was 3.2months (90% CI: 2.1-4.4). The median overall survival was 7.9months (90% CI: 6.1-11.7). More common grade 3 adverse events were hypertension, anemia, hyponatremia, hyperglycemia, elevated liver enzymes, nausea, headache, and colon hemorrhage. Grade 4 adverse events included sepsis and hypertension.ConclusionsBased on early results of this phase II trial, brivanib was well tolerated and demonstrated sufficient activity after first stage but trial was stopped due to lack of drug availability. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| العلاقة: | qt6z5008cr; https://escholarship.org/uc/item/6z5008crTest; https://escholarship.org/content/qt6z5008cr/qt6z5008cr.pdfTest |
| DOI: | 10.1016/j.ygyno.2017.05.033 |
| الإتاحة: | https://doi.org/10.1016/j.ygyno.2017.05.033Test https://escholarship.org/uc/item/6z5008crTest https://escholarship.org/content/qt6z5008cr/qt6z5008cr.pdfTest |
| حقوق: | CC-BY |
| رقم الانضمام: | edsbas.F652F919 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ygyno.2017.05.033 |
|---|